Top 10 Clinical Trends for July 2015

Ryan Syrek


July 22, 2015

#3 Clinical Trend: PCSK9 Inhibitors

Last month, the FDA approved use of an investigational proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor for lowering low-density lipoprotein (LDL) cholesterol levels. The vote was 11-4 in favor of approval. The committee felt the benefits were most notable in patients with heterozygous familial hypercholesterolemia (FH).

For more in-depth clinical information, see Familial Hypercholesterolemia.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.